

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/1/08 Signature: Susan Lanney

JFW

Docket No.: COTH-P02-001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Afeyan et al.

Application No.: 10/650591

Confirmation No.: 7918

Filed: August 27, 2003

Art Unit: 1652

For: ADZYMES AND USES THEREOF

Examiner: Saidha, Tekchand

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. §1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached with the exception of the U.S. patents.

Applicants also enclose a copy of the argument by Richard Wagner that accompanied the untimely filed Protest under 37 C.F.R. §1.291. This document is provided merely in an excess of caution to ensure compliance with the disclosure requirement under Rule 56. Applicants have not yet determined whether or not these arguments are material to the instant application, and no

conclusion regarding materiality should be drawn from the inclusion of these documents in this Supplemental Information Disclosure Statement.

In accordance with 37 C.F.R. §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. COTH-P02-001. A duplicate copy of this paper is enclosed.

Dated: July 1, 2005

Respectfully submitted,

By _____.

Yu Lu, Ph.D.

Registration No.: 50,306
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONMay 31, 2005
(Use several sheets if necessary)FIRST NAMED APPLICANT
Afeyan, Noubar B., et al.FILING DATE
August 27, 2003CONFIRMATION NO.
7918GROUP
1652

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	MM-DD-YYYY ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	4,975,278	12-04-1990	Bristol-Myers Company
	AB	5,258,498	11-02-1993	Huston et al.
	AC	5,961,973	10-05-1999	Crea
	AD	5,811,265	09-22-1998	Quertermous et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	MM-DD-YYYY PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	AL	WO 00/64485 A2	11-02-2000	Genencor International, Inc.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Holvoet, Paul, et al., "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," <i>J. Biological Chemistry</i> , 266(29): 19717-19724 (1991).
AS	Collen, Desire and Lijnen, H. Roger, "New thrombolytic agents and strategies," <i>Baillière's Clinical Haematology</i> , 8(2): 425-435 (1995).



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	COTH-P02-001
-------	---	----	---	------------------------	--------------

Complete if Known

Application Number	10/650591
Filing Date	August 27, 2003
First Named Inventor	Noubar B. Afeyan
Art Unit	1652
Examiner Name	Saidha, Tekchand

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AG	US-4,975,278	12-04-1990	Senter et al.		
AH	US-5,258,498	11-02-1993	Huston et al.		
AI	US-5,811,265	09-22-1998	Quertermous et al.		
AJ	US-5,961,973	10-05-1999	Crea		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
BF	WO 00/64485-A2		11-02-2000	Genencor International, Inc. et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CT	COLLEN, D., et al., "New thrombolytic agents and strategies," <i>Bailliere's Clinical Haematology</i> , 8(2):425-435 (1995).		
CU	HOLVOET, P., et al., "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," <i>The Journal of Biological Chemistry</i> , 266(29):19717-19724 (1991).		
CV	WAGNER, R., Copy of Untimely Filed Protest under 37 C.F.R. § 1.291.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered
--------------------	--	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/650591

Attorney Docket No.: COTH-P02-001


O I P E
JUL 05 2005
PATENT & TRADEMARK OFFICE
SCTG

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 1, 2005
Date


Signature

Susan Lanney

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (7 References) (1 page)
Supplemental Information Disclosure Statement (2 pages)
7 Cited References (AG-AJ, BF, CT-CU)
Copy of Untimely Filed Protest under 37 C.F.R. § 1.291. (CV)
This return receipt postcard